|
|
|
|
| LEADER |
02177nam a2200325 u 4500 |
| 001 |
EB001865313 |
| 003 |
EBX01000000000000001029393 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
190504 r ||| eng |
| 245 |
0 |
0 |
|a Pharmacoeconomic review report: Ocrelizumab (Ocrevus) (Hoffmann-La roche limited)
|h Elektronische Ressource
|
| 246 |
3 |
1 |
|a CADTH common drug review pharmacoeconomic review report for Ocrevus
|
| 246 |
3 |
1 |
|a Ocrelizumab (Ocrevus) (Hoffmann-La roche limited)
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2018, 2018
|
| 300 |
|
|
|a 1 PDF file (25 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Antibodies, Monoclonal, Humanized / economics
|
| 653 |
|
|
|a Immunologic Factors / economics
|
| 653 |
|
|
|a Multiple Sclerosis, Chronic Progressive / drug therapy
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Immunosuppressive Agents / economics
|
| 653 |
|
|
|a Antibodies, Monoclonal, Humanized / therapeutic use
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK533401
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 140
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a Ocrelizumab (Ocrevus) is a recombinant humanized monoclonal antibody that selectively targets and depletes CD20-expressing B-cells, which are thought to contribute to the inflammatory and neurodegenerative pathogenesis of multiple sclerosis (MS). Ocrelizumab is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS), and was previously reviewed by CADTH. The CADTH Canadian Drug Expert Committee recommended that ocrelizumab be listed for RRMS based on the condition of a price reduction of at least 50%. This submission relates to an application to Health Canada for an indication relating to the treatment of adult patients with primary progressive multiple sclerosis (PPMS) to delay disease progression and reduce deterioration in walking speed
|